You are here

  • Home
  • Archive
  • Volume 5, Issue 5
  • Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical tri…

Citation Tools

Article menu
XML
Oncology
Protocol
Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Neychev V, Steinberg SM, Cottle-Delisle C, et al
Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial
BMJ Open 2015;5:e008248. doi: 10.1136/bmjopen-2015-008248